JPRN-jRCTs061180096招募中2 期
Phase II study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer - Phase II study of DCS-T
Takayama Tetsuji0 个研究点目标入组 30 人开始时间: 2019年3月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1)Written informed consent.
- •2)Histologicaly (cytologically) proven gastric cancer.
- •3)HER2 positive by IHC or FISH method
- •4)Unresectable gastric cancer.
- •5)To have measurable lesions.
- •6)No prior chemotherapy or no influence of prior therapy.
- •7)Tolerable function of bone marrow, liver and kidney.
- •8)LVEF more than 50%
- •9)PS 0 - 1.
- •10)Expected survival for 3 months.
- •11)Possible oral intake.
排除标准
- •1)History of hypersensitivity to DCS.
- •2)Contraindication to TXT, CDDP, S-1, G-CSF.
- •3)Infectious disease.
- •4)Severe compliaction.
- •5)Brain metastasis with clinical symptoms.
- •6)Watery diarea.
- •7)Active double cancer.
- •8)Persons to be pregnant or to make pregnant.
研究者
相似试验
招募中
不适用
Phase 2 study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancergastric cancerJPRN-UMIN000012042Tokushima-Hokkaido cancer therapy clinical trial group30
已完成
1 期
Phase I/II Study of S-1, Cisplatin and Docetaxel in Patients with Advanced Gastric Canceruntreated advanced or recurrent gastric cancerJPRN-UMIN000000484Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama40
已完成
1 期
Phase I study of Docetaxel, Cisplatin and S-1 in patients with advanced or recurrent gastric cancerGastric cancerJPRN-UMIN000000978Shizuoka Cancer Center18
招募中
2 期
Phase II study of Docetaxel, Cisplatin and S1 followed by surgery in advanced gastric cancer with lymph node metastasis of the paraaortagastric cancer with para-aortic lymph node metastasisJPRN-UMIN000006036Digestive Disease Support Organization (DDSO)30
招募中
2 期
Phase II study of modified S-1, docetaxel and cisplatin combination chemotherapy (mDCS) in patients with unresectable metastatic gastric cancer.Gastric cancerJPRN-UMIN000002361Tokushima-Hokkaido cancer therapy clinical trial group50